275 related articles for article (PubMed ID: 15096806)
1. Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study.
Martin A; Smith DE; Carr A; Ringland C; Amin J; Emery S; Hoy J; Workman C; Doong N; Freund J; Cooper DA;
AIDS; 2004 Apr; 18(7):1029-36. PubMed ID: 15096806
[TBL] [Abstract][Full Text] [Related]
2. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
Carr A; Workman C; Smith DE; Hoy J; Hudson J; Doong N; Martin A; Amin J; Freund J; Law M; Cooper DA;
JAMA; 2002 Jul; 288(2):207-15. PubMed ID: 12095385
[TBL] [Abstract][Full Text] [Related]
3. Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.
John M; McKinnon EJ; James IR; Nolan DA; Herrmann SE; Moore CB; White AJ; Mallal SA
J Acquir Immune Defic Syndr; 2003 May; 33(1):29-33. PubMed ID: 12792352
[TBL] [Abstract][Full Text] [Related]
4. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy.
Moyle GJ; Sabin CA; Cartledge J; Johnson M; Wilkins E; Churchill D; Hay P; Fakoya A; Murphy M; Scullard G; Leen C; Reilly G;
AIDS; 2006 Oct; 20(16):2043-50. PubMed ID: 17053350
[TBL] [Abstract][Full Text] [Related]
5. Improvements in cheek volume in lipoatrophic individuals switching away from thymidine nucleoside reverse transcriptase inhibitors.
Benn P; Sauret-Jackson V; Cartledge J; Ruff C; Sabin CA; Moyle G; Linney A; Reilly G; Edwards SG
HIV Med; 2009 Jul; 10(6):351-5. PubMed ID: 19490181
[TBL] [Abstract][Full Text] [Related]
6. Peripheral and visceral fat changes following a treatment switch to a non-thymidine analogue or a nucleoside-sparing regimen in HIV-infected subjects with peripheral lipoatrophy: results of ACTG A5110.
Tebas P; Zhang J; Hafner R; Tashima K; Shevitz A; Yarasheski K; Berzins B; Owens S; Forand J; Evans S; Murphy R
J Antimicrob Chemother; 2009 May; 63(5):998-1005. PubMed ID: 19299471
[TBL] [Abstract][Full Text] [Related]
7. A 48-week, randomized, open-label comparison of three abacavir-based substitution approaches in the management of dyslipidemia and peripheral lipoatrophy.
Moyle GJ; Baldwin C; Langroudi B; Mandalia S; Gazzard BG
J Acquir Immune Defic Syndr; 2003 May; 33(1):22-8. PubMed ID: 12792351
[TBL] [Abstract][Full Text] [Related]
8. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).
Eron JJ; Murphy RL; Peterson D; Pottage J; Parenti DM; Jemsek J; Swindells S; Sepulveda G; Bellos N; Rashbaum BC; Esinhart J; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1601-10. PubMed ID: 10983647
[TBL] [Abstract][Full Text] [Related]
9. Progression of lipodystrophy (LD) with continued thymidine analogue usage: long-term follow-up from a randomized clinical trial (the PIILR study).
Martin A; Smith D; Carr A; Hoy J; Chuah J; Mallal S; Law M; Clements M; Cooper DA;
HIV Clin Trials; 2004; 5(4):192-200. PubMed ID: 15472793
[TBL] [Abstract][Full Text] [Related]
10. Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine.
McComsey GA; Paulsen DM; Lonergan JT; Hessenthaler SM; Hoppel CL; Williams VC; Fisher RL; Cherry CL; White-Owen C; Thompson KA; Ross ST; Hernandez JE; Ross LL
AIDS; 2005 Jan; 19(1):15-23. PubMed ID: 15627029
[TBL] [Abstract][Full Text] [Related]
11. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
12. Objective assessment of facial lipoatrophy changes in a cohort of HIV-infected patients taking combination antiretroviral therapy.
Yang Y; Yap M; Oo Tha N; Paton NI
HIV Clin Trials; 2008; 9(6):399-406. PubMed ID: 19203905
[TBL] [Abstract][Full Text] [Related]
13. Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: role of physical activity as a protective factor.
Domingo P; Sambeat MA; Pérez A; Ordoñez J; Rodriguez J; Vázquez G
Antivir Ther; 2003 Jun; 8(3):223-31. PubMed ID: 12924539
[TBL] [Abstract][Full Text] [Related]
14. Switching to lopinavir/ritonavir with or without abacavir/lamivudine in lipoatrophic patients treated with zidovudine/abacavir/lamivudine.
Bernardino JI; Pulido F; Martinez E; Arrizabalaga J; Domingo P; Portilla J; Ocampo A; Muñoz J; Torres R; Arribas JR;
J Antimicrob Chemother; 2013 Jun; 68(6):1373-81. PubMed ID: 23386261
[TBL] [Abstract][Full Text] [Related]
15. From old to new nucleoside reverse transcriptase inhibitors: changes in body fat composition, metabolic parameters and mitochondrial toxicity after the switch from thymidine analogs to tenofovir or abacavir.
Curran A; Ribera E
Expert Opin Drug Saf; 2011 May; 10(3):389-406. PubMed ID: 21235431
[TBL] [Abstract][Full Text] [Related]
16. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study.
McComsey GA; Ward DJ; Hessenthaler SM; Sension MG; Shalit P; Lonergan JT; Fisher RL; Williams VC; Hernandez JE;
Clin Infect Dis; 2004 Jan; 38(2):263-70. PubMed ID: 14699460
[TBL] [Abstract][Full Text] [Related]
17. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study).
Ribera E; Paradiñeiro JC; Curran A; Sauleda S; García-Arumí E; Castella E; Puiggròs C; Crespo M; Feijoo M; Diaz M; Del Saz SV; Planas M; Sureda D; Falcó V; Ocaña I; Pahissa A
HIV Clin Trials; 2008; 9(6):407-17. PubMed ID: 19203906
[TBL] [Abstract][Full Text] [Related]
18. Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study.
Podzamczer D; Ferrer E; Sanchez P; Gatell JM; Crespo M; Fisac C; Lonca M; Sanz J; Niubo J; Veloso S; Llibre JM; Barrufet P; Ribas MA; Merino E; Ribera E; Martínez-Lacasa J; Alonso C; Aranda M; Pulido F; Berenguer J; Delegido A; Pedreira JD; Lérida A; Rubio R; del Río L;
J Acquir Immune Defic Syndr; 2007 Feb; 44(2):139-47. PubMed ID: 17106274
[TBL] [Abstract][Full Text] [Related]
19. Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from Stavudine to abacavir or zidovudine.
Cherry CL; Lal L; Thompson KA; McLean CA; Ross LL; Hernandez J; Wesselingh SL; McComsey G
J Acquir Immune Defic Syndr; 2005 Mar; 38(3):263-7. PubMed ID: 15735442
[TBL] [Abstract][Full Text] [Related]
20. Impact of switching from zidovudine/lamivudine to tenofovir/emtricitabine on lipoatrophy: the RECOMB study.
Ribera E; Larrousse M; Curran A; Negredo E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Ferrer P; Alvarez ML; Arterburn S; Martínez E
HIV Med; 2013 Jul; 14(6):327-36. PubMed ID: 23298339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
